Analysts Set Expectations for TVRD Q2 Earnings

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) – HC Wainwright issued their Q2 2026 EPS estimates for shares of Tvardi Therapeutics in a research note issued to investors on Monday, June 8th. HC Wainwright analyst S. Nik expects that the company will post earnings per share of ($0.78) for the quarter. HC Wainwright currently has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for Tvardi Therapeutics’ current full-year earnings is ($2.10) per share. HC Wainwright also issued estimates for Tvardi Therapeutics’ Q3 2026 earnings at ($0.86) EPS, Q4 2026 earnings at ($1.17) EPS, FY2026 earnings at ($3.54) EPS, FY2027 earnings at ($6.52) EPS and FY2028 earnings at ($6.86) EPS.

TVRD has been the subject of several other reports. Weiss Ratings restated a “sell (e+)” rating on shares of Tvardi Therapeutics in a research report on Friday, April 10th. Wall Street Zen cut Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 4th. Finally, BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Tvardi Therapeutics in a report on Wednesday, April 1st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Tvardi Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $46.17.

Tvardi Therapeutics Stock Performance

Shares of TVRD opened at $2.78 on Wednesday. Tvardi Therapeutics has a 52-week low of $2.75 and a 52-week high of $43.65. The business’s fifty day moving average is $3.34 and its 200-day moving average is $3.77. The firm has a market cap of $26.08 million, a price-to-earnings ratio of -0.90 and a beta of 0.33.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings data on Friday, May 8th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.08).

Hedge Funds Weigh In On Tvardi Therapeutics

Several large investors have recently bought and sold shares of the company. XTX Topco Ltd acquired a new position in Tvardi Therapeutics in the 4th quarter valued at approximately $55,000. Quadrature Capital Ltd bought a new stake in shares of Tvardi Therapeutics in the fourth quarter worth $90,000. Russell Investments Group Ltd. grew its stake in shares of Tvardi Therapeutics by 1,351.5% in the fourth quarter. Russell Investments Group Ltd. now owns 15,966 shares of the company’s stock worth $69,000 after purchasing an additional 14,866 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in Tvardi Therapeutics by 534.3% during the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock worth $223,000 after buying an additional 43,619 shares during the period. Finally, Arax Advisory Partners grew its position in shares of Tvardi Therapeutics by 277.2% in the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after buying an additional 6,173 shares during the last quarter. 44.66% of the stock is currently owned by institutional investors.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.